A Physiologically Based Pharmacokinetic (PBPK) Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions Between an Anti-Interleukin-6 (IL-6) Monoclonal Antibody (Sarilumab) and Multiple Cytochrome P450 (CYP) Substrates in Patients with Rheumatoid Arthritis (RA)

Xu Christine R.; Paccaly Anne; Kanamaluru Vanaja

首页> 外文期刊>Journal of pharmacokinetics and pharmacodynamics >A Physiologically Based Pharmacokinetic (PBPK) Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions Between an Anti-Interleukin-6 (IL-6) Monoclonal Antibody (Sarilumab) and Multiple Cytochrome P450 (CYP) Substrates in Patients with Rheumatoid Arthritis (RA)

【24h】

A Physiologically Based Pharmacokinetic (PBPK) Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions Between an Anti-Interleukin-6 (IL-6) Monoclonal Antibody (Sarilumab) and Multiple Cytochrome P450 (CYP) Substrates in Patients with Rheumatoid Arthritis (RA)

机译：一种基于生理学的药代动力学（PBPK）模型，以预测抗白细胞介素-6（IL-6）单克隆抗体（Sarilumab）与类风湿性关节炎患者抗白细胞介素-6（IL-6）单克隆抗体（Sarilumab）和多种细胞色素P450（CYP）底物之间的疾病介导的治疗蛋白 - 药物相互作用（RA 的）

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of pharmacokinetics and pharmacodynamics》 |2018年第suppla期|共1页
作者
Xu Christine R.; Paccaly Anne; Kanamaluru Vanaja;
展开▼
作者单位

Sanofi Genzyme Bridgewater NJ USA;

Regeneron Pharmaceut Inc 777 Old Saw Mill River Rd Tarrytown NY 10591 USA;

Sanofi Genzyme Bridgewater NJ USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药学;
关键词
入库时间 2022-08-20 09:57:40

相似文献

外文文献

1. A Physiologically Based Pharmacokinetic (PBPK) Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions Between an Anti-Interleukin-6 (IL-6) Monoclonal Antibody (Sarilumab) and Multiple Cytochrome P450 (CYP) Substrates in Patients with Rheumatoid Arthritis (RA) [J] . Xu Christine R., Paccaly Anne, Kanamaluru Vanaja Journal of pharmacokinetics and pharmacodynamics . 2018,第Suppla期

机译：一种基于生理学的药代动力学（PBPK）模型，以预测抗白细胞介素-6（IL-6）单克隆抗体（Sarilumab）与类风湿性关节炎患者抗白细胞介素-6（IL-6）单克隆抗体（Sarilumab）和多种细胞色素P450（CYP）底物之间的疾病介导的治疗蛋白 - 药物相互作用（RA 的）
2. Predicting the Effect of CYP3A Inducers on the Pharmacokinetics of Substrate Drugs Using Physiologically Based Pharmacokinetic (PBPK) Modeling: An Analysis of PBPK Submissions to the US FDA [J] . Wagner Christian, Pan Yuzhuo, Hsu Vicky, Clinical pharmacokinetics . 2016,第4期

机译：使用基于生理学的药代动力学（PBPK）建模预测CYP3A诱导剂对底物药物的药代动力学的影响：PBPK提交给美国FDA的分析
3. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children [J] . Zhou Wangda, Johnson Trevor N., Bui Khanh H., Clinical Pharmacology and Therapeutics . 2018,第1期

机译：基于生理学药代动力学（PBPK）模型的预测性能通过主要细胞学P450S在儿童中广泛代谢
4. Use of Cytochrome P450-Specific Parameters and Human Biomarker Data To Develop a Human Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Dermal Chlorpyrifos Exposure [C] . Corie A. Ellison, James B. Knaak, Robin McDougall, ACS national meeting . 2012

机译：使用细胞色素P450特定参数和人类生物标志物数据开发针对皮毒死Expo暴露的人体生理学药代动力学/药效学模型
5. Physiologically-based Pharmacokinetic and Pharmacodynamic (PBPK/PD) Predictive Brain Toxicity Computational Model for Organophosphates. [D] . Akwitti, Chukwuma. 2017

机译：基于生理学的药代动力学和药效学（PBPK / PD）预测性有机磷的脑毒性计算模型。
6. Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein–Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6 [O] . Xiling Jiang, Yanli Zhuang, Zhenhua Xu, 2016

机译：基于生理的药代动力学模型的开发以预测疾病介导的治疗性蛋白质-药物相互作用：白介素6对多种细胞色素P450酶的调节
7. Development of a Physiologically Based Pharmacokinetic Model to Predict Disease-Mediated Therapeutic Protein–Drug Interactions: Modulation of Multiple Cytochrome P450 Enzymes by Interleukin-6 [O] . Xiling Jiang, Yanli Zhuang, Zhenhua Xu, 2016

机译：基于生理学的药代动力学模型，预测疾病介导的治疗蛋白 - 药物相互作用：白细胞介素-6的多种细胞色素P450酶的调节

A Physiologically Based Pharmacokinetic (PBPK) Model to Predict Disease-Mediated Therapeutic Protein-Drug Interactions Between an Anti-Interleukin-6 (IL-6) Monoclonal Antibody (Sarilumab) and Multiple Cytochrome P450 (CYP) Substrates in Patients with Rheumatoid Arthritis (RA)

著录项

相似文献

相关主题

期刊订阅